Due for completion in 2028, the Sydney Biomedical Accelerator will be a globally significant hub for biomedical research, innovation, and translation in Sydney, Australia. Currently in the construction phase, the Sydney Biomedical Accelerator (SBA) is a visionary partnership between the University of Sydney, Sydney Local Health District, and the NSW Government. The partnership brings together clinicians, researchers, academics, and industry to solve some of the world’s most complex health challenges. It will provide a compelling platform for international collaboration, offering partners opportunities to engage in joint research, clinical translation, and industry-led innovation. When built and operational, the SBA will support innovative research, translation, and commercialisation, fast-tracking scientific discovery into better health outcomes. Capitalising on the University of Sydney’s international collaborations, particularly its longstanding partnership with Europe, the SBA will benefit significantly from existing relationships and collaborations as it works towards a vision closely aligned with the overarching direction of European framework programmes. To find out more about the SBA and what it will do for Australia’s medical research landscape, The Innovation Platform spoke with Professor …